Evidence map›Paper›PMID 33836039›Full record

ReviewJornal brasileiro de nefrologia

COVID-19 and chronic kidney disease: a comprehensive review.

Inah Maria D Pecly, Rafael B Azevedo, Elizabeth S Muxfeldt, Bruna G Botelho, Gabriela G Albuquerque, Pedro Henrique P Diniz, Rodrigo Silva, Cibele I S Rodrigues

Open access · diamondAbstract readReview
In one paragraph

Review in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Post-COVID-19 inflammation and sarcopenia in obese diabetic dialysis patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
    Article
  3. Temporal trends in healthcare resource use and costs of chronic kidney disease in a Spanish population: the REDIC study.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  4. Article
  5. Recurrent stroke admissions withWorld journal of virology · 2024
    Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Clinical manifestations of COVID-19 infection in dialysis patients and protective effect of COVID-19 vaccine.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Review
  15. Hybrid model for early identification post-Covid-19 sequelae.Journal of ambient intelligence and humanized computing · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Analysis of Survival of Patients Hospitalized with COVID-19 in Espírito Santo, Brazil.International journal of environmental research and public health · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Inah Maria D PeclyUniversidade Estácio de Sá, Curso de Medicina Rio de Janeiro, Campus Centro I - Presidente Vargas, Rio de Janeiro, RJ, Brasil.ORCID http://orcid.org/0000-0002-1043-0907
Rafael B AzevedoUniversidade Estácio de Sá, Curso de Medicina Rio de Janeiro, Campus Centro I - Presidente Vargas, Rio de Janeiro, RJ, Brasil.ORCID http://orcid.org/0000-0001-6864-8805
Elizabeth S MuxfeldtUniversidade Estácio de Sá, Curso de Medicina Rio de Janeiro, Campus Centro I - Presidente Vargas, Rio de Janeiro, RJ, Brasil.ORCID http://orcid.org/0000-0003-3853-7842
Bruna G BotelhoUniversidade Estácio de Sá, Curso de Medicina Rio de Janeiro, Campus Centro I - Presidente Vargas, Rio de Janeiro, RJ, Brasil.ORCID http://orcid.org/0000-0002-4130-5148
Gabriela G AlbuquerqueUniversidade Estácio de Sá, Curso de Medicina Rio de Janeiro, Campus Centro I - Presidente Vargas, Rio de Janeiro, RJ, Brasil.ORCID http://orcid.org/0000-0003-1433-1911
Pedro Henrique P DinizUniversidade Estácio de Sá, Curso de Medicina Rio de Janeiro, Campus Centro I - Presidente Vargas, Rio de Janeiro, RJ, Brasil.ORCID http://orcid.org/0000-0001-7081-2977
Rodrigo SilvaUniversidade Estácio de Sá, Curso de Medicina Rio de Janeiro, Campus Centro I - Presidente Vargas, Rio de Janeiro, RJ, Brasil.ORCID http://orcid.org/0000-0001-9612-6609
Cibele I S RodriguesPontifícia Universidade Católica de São Paulo, Faculdade de Ciências Médicas e da Saúde, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0001-9490-7997
Universidade do Estado do Rio de Janeiro · BRPontifícia Universidade Católica de São Paulo · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney impairment in hospitalized patients with SARS-CoV-2 infection is associated with increased in-hospital mortality and worse clinical evolution, raising concerns towards patients with chronic kidney disease (CKD). From a pathophysiological perspective, COVID-19 is characterized by an overproduction of inflammatory cytokines (IL-6, TNF-alpha), causing systemic inflammation and hypercoagulability, and multiple organ dysfunction syndrome. Emerging data postulate that CKD under conservative treatment or renal replacement therapy (RRT) is an important risk factor for disease severity and higher in-hospital mortality amongst patients with COVID-19. Regarding RAAS blockers therapy during the pandemic, the initial assumption of a potential increase and deleterious impact in infectivity, disease severity, and mortality was not evidenced in medical literature. Moreover, the challenge of implementing social distancing in patients requiring dialysis during the pandemic prompted national and international societies to publish recommendations regarding the adoption of safety measures to reduce transmission risk and optimize dialysis treatment during the COVID-19 pandemic. Current data convey that kidney transplant recipients are more vulnerable to more severe infection. Thus, we provide a comprehensive review of the clinical outcomes and prognosis of patients with CKD under conservative treatment and dialysis, and kidney transplant recipients and COVID-19 infection.

Indexed as

COVID-19Renal Insufficiency, ChronicHumansPandemicsRenal DialysisSARS-CoV-2

Identifiers

PMID33836039
PMCPMC8428633
OpenAlexW3145728711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.